Non-Opioid Analgesics Acetaminophen & Dipyrone (Metamizole)

Acetaminophen has limited effectiveness as a standalone treatment for myofascial pain syndrome. It does not address the key pathophysiological mechanisms of trigger points: it does not reduce peripheral inflammation around the trigger point, does not relax the taut band or contracted sarcomeres, does not improve local blood flow to ischemic trigger point tissue, and does not modulate the peripheral sensitization driven by accumulated algogenic substances (bradykinin, substance P, CGRP, serotonin, prostaglandins) within the trigger point milieu.

Where acetaminophen provides value in myofascial pain management is in mild background pain relief and as an adjunct in multimodal therapy. It is best combined with an NSAID (for additive analgesia through different mechanisms), a muscle relaxant (to address the contracture component), or used as a pre-treatment before physical therapy or dry needling sessions to improve patient comfort during these procedures.

Dipyrone (metamizole sodium) is a pyrazolone derivative first synthesized in 1920 and introduced to clinical use in 1922. Known by its International Nonproprietary Name (INN) metamizole, it is marketed under dozens of brand names worldwide, including Novalgin in Germany, Analgin in Russia and Eastern Europe, and various regional brands in Latin America. It is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to its primary active metabolite, 4-methylaminoantipyrine (4-MAA), which is further metabolized to 4-aminoantipyrine (4-AA) and other metabolites.

Dipyrone holds a remarkable and paradoxical position in global pharmacology. It is the most prescribed analgesic in several large markets, including Latin America and Germany, where it is the most prescribed non-opioid analgesic for moderate to severe pain. Yet it has been banned in the United States since 1977 and is unavailable in the United Kingdom, Australia, Japan, and Canada — primarily due to concerns about agranulocytosis, a rare but potentially fatal blood disorder.

This global divide makes dipyrone one of the most politically and scientifically controversial medications in the world. Understanding its pharmacology, risks, and benefits is essential for clinicians treating myofascial pain in populations where dipyrone is a first-line option, and for patients from countries where dipyrone is standard who may seek equivalent alternatives when traveling or living in countries where it is banned.

Dipyrone offers moderate effectiveness for myofascial pain syndrome, exceeding acetaminophen due to its stronger analgesic potency and unique spasmolytic action. The direct muscle relaxant effect — reducing taut band tension through calcium signaling modulation — addresses a component of trigger point pathophysiology that acetaminophen cannot touch. Additionally, the activation of both opioidergic and cannabinoidergic descending pathways provides broader pain modulation than acetaminophen's primarily serotonergic mechanism.

In countries where dipyrone is available, the combination product dipyrone + orphenadrine + caffeine (dipyrone 300mg + orphenadrine 35mg + caffeine 50mg) is a popular OTC treatment for muscle pain and is widely used by myofascial pain patients. This combination is pharmacologically rational: dipyrone provides central analgesia and spasmolysis, orphenadrine provides anticholinergic muscle relaxation and mild analgesic effects, and caffeine enhances absorption and adds mild adenosine-receptor-mediated analgesia. Many physiotherapists and pain specialists recommend this combination as a first-line OTC option for acute myofascial pain flares where available.

The central controversy surrounding dipyrone is its association with agranulocytosis — a severe, potentially fatal condition characterized by a dramatic reduction in granulocytes (neutrophils) to below 500 cells/microL. Agranulocytosis caused by dipyrone is an idiosyncratic, immune-mediated reaction (type II hypersensitivity) in which drug-dependent antibodies target granulocyte precursors in the bone marrow. It is not dose-dependent and cannot be predicted by any available test.

The risk has been estimated at anywhere from 0.03 to 0.5 cases per million treatments, depending on the study population, methodology, and geographic region. This enormous range in estimates reflects the fundamental difficulty of measuring extremely rare adverse events and has fueled decades of scientific and regulatory debate.